Sectors

TEVA
Teva Pharmaceutical Industries Limited
34.46
1 x 33.81
1 x 34.74
bid
ask
-
0.55
1.57%
40 @ 04:00 PM
34.17 -0.29 (0.85%)
Ytd10.41%
1y124.06%
33.78
day range
35.06
15.46
52 week range
37.35
Open35.02Prev Close35.01Low33.78High35.06Mkt Cap40.13B
Vol6.21MAvg Vol5.97MEPS2.93P/E11.76Forward P/E15.50
Beta0.86Short Ratio5.60Inst. Own62.40%DividendN/ADiv YieldN/A
Ex Div Date11-27Earning07-2950-d Avg33.30200-d Avg30.721yr Est40.90
Earning
DateForEstimateReportedSurprisesurprise %
2026-11-042026-090.72N/AN/AN/A
2026-07-292026-060.080.02-0.06-75.00%
2026-04-292026-030.50.530.036.00%
2026-01-282025-120.650.960.3147.69%
2025-11-052025-090.680.780.114.71%
2025-07-302025-060.630.660.034.76%
Upgrade / Downgrade
DateFirmActionFromTo
2026-05-06BarclaysUpgradeOverweightOverweight
2026-04-30JP MorganUpgradeOverweightOverweight
2026-04-30UBSUpgradeBuyBuy
2026-04-30Piper SandlerUpgradeOverweightOverweight
2026-04-30Truist SecuritiesUpgradeBuyBuy
2026-04-09B of A SecuritiesUpgradeBuyBuy
Profile
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Insider Holder
DateNameRelationQuantityDescription
2025-06-05CRANE ROSEMARY ADirector113.25KConversion of Exercise of derivative security
2026-03-02DANIELL RICHARDOfficer123.13KConversion of Exercise of derivative security
2025-06-05ELSTEIN AMIRDirector2.10MConversion of Exercise of derivative security
2026-03-04FRANCIS RICHARD DChief Executive Officer1.17MConversion of Exercise of derivative security
2026-03-04HUGHES ERIC AOfficer107.71KConversion of Exercise of derivative security
2026-03-04KALIF ELIYAHU SHARONChief Financial Officer325.44KConversion of Exercise of derivative security
Institution Ownership
Report DateOrganizationPositionValuePercentage
2026-03-30BlackRock Inc65.14M0.005.59%
2026-03-30Harel Insurance Invests & Fin Srvcs Ltd45.96M0.003.95%
2026-03-30Phoenix Financial Ltd42.78M0.003.67%
2026-03-30WCM Investment Management40.82M0.003.51%
2026-03-30MENORA MIVTACHIM HOLDINGS LIMITED39.63M0.003.40%
2026-03-30Clal Insurance Enterprises Holdings Ltd38.45M0.003.30%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-03-30WCM Focused International Growth Instl13.25M0.001.14%
2026-05-28iShares Core MSCI EAFE ETF8.65M0.000.74%
2026-03-30American Funds New Economy A5.84M0.000.50%
2026-03-30Capital Group New Economy Comp5.84M0.000.50%
2026-03-30EAFE Equity Index Fund T5.48M0.000.47%
2026-04-29Fidelity Contrafund5.44M0.000.47%
Dividend
DividendDate
0.0852017-11-27
0.0852017-08-25
0.342017-06-01
0.342017-02-28
0.342016-12-01
0.342016-08-18
Split
SplitDate
2 : 12004-07-01
2 : 12002-12-06
2 : 12000-02-23
2 : 11993-04-14
1 : 11982-08-16